Search
Close
Search
Advanced Search
Search Menu
AI Research Assistant

Extract

LONG-TERM BISPHOSPHONATE USERS AND THEIR DOCTORS were warned recently by the U.S. Food and Drug Administration about these patients’ possible risk of atypical femoral fractures. A labeling change and Medication Guide for bisphosphonates approved for osteoporosis will reflect this risk.

(www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229171.htm)

MERIDIA (SIBUTRAMINE), an obesity drug manufactured by Abbott Laboratories, was recently withdrawn from the U.S. market because postmarket clinical trial data indicated an increased risk of heart attack and stroke and no weight loss difference between those that received the drug and those on placebo. The European Medicines Agency already suspended all sibutramine-containing drugs this past January.

( www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm228812.htm )

ESTROGEN THERAPY IN HEALTHY POSTMENOPAUSAL WOMEN was associated with a significant increase in nephrolithiasis, independent of progestin coadministration, according to a randomized, placebo-controlled study of 27,347 postmenopausal women with and without prior hysterectomy.

(
Arch Intern Med
[October 11, 2010] 170 (18):1678)

BODY SIZE MISPERCEPTION, or the failure to recognize the need to lose weight, was detected in about 8% of obese U.S. adults. This phenomenon, found particularly in ethnic minorities, may be a novel obesity treatment target.

Issue Section:
The Endocrine Society
You do not currently have access to this article.
Download all slides